| 5′ N | 5′ nucleotidase |
| AD | Alzheimer’s disease |
| AMD | Age-related macular degeneration |
| AT1-R | Angiotensin II type-1 receptor |
| β-AR | β-adrenergic receptor |
| BRB | Blood-retinal barrier |
| COX | Cyclooxygenase |
| DHA | Docosahexaenoic |
| DR | Diabetic retinopathy |
| EPA | Eicosapentaenoic |
| eEPC | Early endothelial progenitor cells |
| Epo | Erythropoietin |
| FDA | Food and Drug Administration |
| G-CSF | Granulocyte colony-stimulating factor |
| HIF | Hypoxia-inducible factor |
| HRE | Hypoxia response element |
| HSPG | Heparin sulphate proteoglycans |
| IGF-1 | Insulin-like growth factor-1 |
| KDR | Kinase insert domain-containing receptor |
| KLT-1 | Kms-related tyrosine kinase 1 |
| mTOR | Mammalian target of rapamycin |
| NOS | Nitric oxide synthetase |
| NRP | Neurophilin |
| ω-3 PUFAs | Omega-3 long-chain polyunsaturated fatty acids |
| OIR | Oxygen-induced retinopathy |
| OPC | Outgrowth endothelial cells |
| PD | Parkinson’s disease |
| PHD | Prolyl hydroxylase |
| RAS | Renin-angiotensin system |
| RGC | Retinal ganglion cells |
| ROP | Retinopathy of prematurity |
| ROS | Reactive oxygen species |
| SC | Stem cell |
| SRPK1 | Serine arginine protein kinase 1 |
| SRSF1 | Serine-rich splicing factor-1 |
| STOP-ROP | Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity |
| VEGF | Vascular endothelial growth factor |